HBV Status of Sexual Assault Survivor | HBsAg Status of Assailant | |||||
---|---|---|---|---|---|---|
HBsAg Positive | HBsAg Status Unknown | HBsAg Negative | ||||
Unvaccinated | HBIG x 1, and HBV vaccine series (first dose now) |
HBV vaccine series (first dose now) | HBV vaccine series (first dose now) | |||
Partially vaccinated | HBIG x 1, and complete HBV vaccine series |
Complete HBV vaccine series (give next dose in series now) | Complete HBV vaccine series (give next dose in series now) | |||
Fully vaccinated but response to vaccine unknown | HBV vaccine booster dose x 1 (give dose now) | HBV vaccine booster dose x 1 (give dose now) | No treatment | |||
Fully vaccinated with documented response to vaccine* | No treatment | No treatment | No treatment | |||
Vaccine nonresponder^ | HBIG x 2 (separated by 1 month) | HBIG x 2 (separated by 1 month) | No treatment | |||
Abbreviations: HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; HBIG = hepatitis B immune globulin |
- Tanner MR, O'Shea JG, Byrd KM, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025. MMWR Recomm Rep. 2025;74:1-56. [PubMed Abstract]
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Sexual assault and abuse and STIs: adolescents and adults. MMWR Recomm Rep. 2021;70(No. RR-4):1-187. [2021 STI Treatment Guidelines]
- Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. Sexual assault and abuse and STDs. MMWR Recomm Rep. 2015;64(No. RR-3):1-137. [2015 STD Treatment Guidelines]
Table 1. 2021 STI Treatment Guidelines: Sexual AssaultEmpiric Antimicrobial Treatment after Sexual Assault
Ceftriaxone
Tradename:RocephinDoxycycline
Tradename:Doryx, VibramycinMetronidazole
Tradename:FlagylCeftriaxone
Tradename:RocephinDoxycycline
Tradename:Doryx, VibramycinExposure Type | Rate for HIV Acquisition per 10,000 Exposures |
---|---|
Parenteral | |
Blood transfusion | 9,250 |
Needle sharing during injection drug use | 63 |
Percutaneous (needlestick) | 23 |
Sexual | |
Receptive anal intercourse | 138 |
Insertive anal intercourse | 11 |
Receptive penile-vaginal intercourse | 8 |
Insertive penile-vaginal intercourse | 4 |
Receptive oral intercourse | Low |
Insertive oral intercourse | Low |
Other^ | |
Biting | Negligible |
Spitting | Negligible |
Throwing body fluids (including semen or saliva) | Negligible |
Sharing sex toys | Negligible |
*Factors that may increase the risk of HIV transmission include sexually transmitted diseases, acute and late-stage HIV infection, and high viral load. Factors that may decrease the risk include condom use, male circumcision, antiretroviral treatment, and preexposure prophylaxis. None of these factors are accounted for in the estimates presented in the table. |
- Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, and Other Nonoccupational Exposure to HIV – United States, 2016. [CDC]
- Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28:1509-19. [PubMed Abstract]
Adults and Adolescents Aged ≥12 years (with creatinine clearance ≥50 mL/min) | |
Preferred |
Integrase Strand Transfer Inhibitor PLUS Two Nucleoside Reverse Transcriptase Inhibitors
|
Alternative |
Boosted Protease Inhibitor PLUS Two Nucleoside Reverse Transcriptase Inhibitors
|
Pregnant Women (with creatinine clearance ≥50 mL/min) | |
Preferred |
Integrase Strand Transfer Inhibitor PLUS Two Nucleoside Reverse Transcriptase Inhibitors
|
Alternative |
Boosted Protease Inhibitor PLUS Two Nucleoside Reverse Transcriptase Inhibitors
|
*The regimens within categories are listed in alphabetical order and not to preference. |
- Tanner MR, O'Shea JG, Byrd KM, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025. MMWR Recomm Rep. 2025;74:1-56. [PubMed Abstract]
Test | Source | Exposed | ||||
---|---|---|---|---|---|---|
Baseline | Baseline | 4-6 Weeks after exposure | 12 weeks after exposure | 6 Months after exposure | ||
All persons evaluated for nPEP | ||||||
Rapid (point-of-care) or laboratory-based HIV Ag/Ab test)† | √ | √ | √§ | √ | — | |
HIV diagnostic NAT¶ | √** | √** | √§ | √ | — | |
HBV serology, including: HBsAg, HBsAb, and HBcAb | √ | √†† | — | — | If HBV nonimmune at baseline | |
HCV antibody testing | — | √§§ | — | — | If follow-up testing recommended¶¶ | |
HCV RNA NAT | √*** | — | If follow-up testing recommended††† | — | — | |
Syphilis serology§§§ | √ | √ | √§§§ | √§§§ | — | |
Gonorrhea NAAT**** | √ | √ | — | — | — | |
Chlamydia NAAT**** | √ | √ | — | — | — | |
Pregnancy test†††† | — | √ | √ | — | — | |
All persons considered for or prescribed nPEP | ||||||
Serum creatinine | √ | Only if abnormalities at baseline | — | — | ||
Alanine aminotransferase and aspartate aminotransferase | √ | Only if abnormalities at baseline or symptomatic | — | — | ||
Abbreviations: Ag/Ab = antigen/antibody combination test; ARV = antiretroviral; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; HBV= hepatitis B virus; HCV = hepatitis C virus; NAT = nucleic acid test; NAAT = nucleic acid amplification test; nPEP = nonoccupational postexposure prophylaxis; PEP = postexposure prophylaxis; STI = sexually transmitted infection. *Any person diagnosed with an infection or condition through testing should be informed and treated or referred for treatment as needed. |
- Tanner MR, O'Shea JG, Byrd KM, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025. MMWR Recomm Rep. 2025;74:1-56. [PubMed Abstract]
Laboratory Test | Sexual Assault Survivor | Alleged Assailant |
---|---|---|
Hepatitis B surface antibody (anti-HBs) | Negative | Negative |
Hepatitis B surface antigen (HBsAg) | Negative | Positive |
Hepatitis B core antibody (anti-HBc) | Negative | Positive |
Hepatitis C antibody | Negative | Negative |
HIV-1/2 antigen-antibody | Negative | Negative |
HBsAg | anti-HBs | anti-HBc | Interpretation | Recommended Action |
---|---|---|---|---|
(+) | (-) | (+) | Chronic HBV infection | Link to care for HBV treatment |
(+) | (-) | IgM (+) | Acute HBV infection | Link to care for management and follow-up |
(-) | (+) | (+) | Resolved HBV infection | Reassurance |
(-) | (+) | (-) | Immune to HBV | Reassurance |
(-) | (-) | (-) | Susceptible to HBV (non immune) | Vaccinate |
(-) | (-) | (+) |
"Isolated anti-HBc" may represent (1) prior HBV infection, (2) a false-positive test, (3) occult HBV infection, or (4) window phase of acute HBV infection |
Expert consultation advised to determing optional further evaluation and management. |
Abbreviations: HBV= hepatitis B Virus; HbsAg = hepatitis B surface antigen; anti-HBs = hepatitis B surface antibody; anti-HBc = hepatitis B core antibody |
Sexually Transmitted Infection | Sexual Abuse | Suggested Action | ||||
---|---|---|---|---|---|---|
Chlamydia trachomatis | Diagnostic* | Report | ||||
Neisseria gonorrhoeae | Diagnostic* | Report | ||||
HIV | Diagnostic** | Report | ||||
Syphilis | Diagnostic* | Report | ||||
Trichomonas vaginalis | Highly suspicious | Report | ||||
Anogenital warts | Suspicious* | Report | ||||
Herpes simplex virus (genital location) | Suspicious^ | Report | ||||
Bacterial vaginosis | Inconclusive | Medical follow-up | ||||
*If not acquired perinatally and rare, nonsexual vertical transmission can be excluded. **If not acquired perinatally, through breastfeeding, or transfusion. ^Autoinoculation should be excluded. Adapted from: Kellogg N. The evaluation of sexual abuse in children. Pediatrics. 2005;116:506-12. |
- Kellogg N. The evaluation of sexual abuse in children. Pediatrics. 2005;116:506-12. [PubMed Abstract]